Startup CytomX has unveiled new preclinical data showing that its fast-working antibody was effective in pancreatic cancer models as both a single agent and in combination with a currently approved cancer drug.
A blood test that screens for two genes could help uncover drastically early signs of pancreatic cancer or spot patients at risk of developing it, researchers believe. Their test could be an important step in reducing mortality from the disease.
Research presented at the International Conference on Molecular Targets and Cancer Therapeutics this week in Boston could point the way to new therapies to treat pancreatic cancer.
While some investigators are seeking better ways to treat pancreatic cancer, others have been tracking biomarkers that can offer a more accurate way to identify the lethal disease earlier on, so patients can be treated while there's a greater chance of fighting the disease.
Pancreatic cancer has long remained one of the toughest targets in the oncology drug field. But an investigator says targeting a biomarker known as phosphatidylserine could greatly improve the odds of coming up with an effective therapy.
The FDA today approved Celgene's Abraxane for pancreatic cancer, an approval that provides some hope for extending the lives of patients with the aggressive cancer. It should also significantly extend the earnings power of the drug, which is already approved for breast and lung cancers.
Tokyo scientists came up with a blood test that they say helps spot pancreatic cancer in its early stages, a crucial advance that could help boost survival rates.
Incyte shares shot up more than 20% ahead of the bell on Wednesday as its blood cancer drug Jakafi turned in positive survival data for pancreatic cancer patients.
The group of drugs, known as incretin mimetics, was cleared last week by FDA's counterparts in Europe.
Earlier this year, a study linked the GLP-1 class of drugs for Type 2 diabetes to an increased risk of pancreatic cancer. Today, the European Medicines Agency said the data just are not substantial enough to make the connection.